Sintilimab, Stereotactic Body Radiotherapy and Granulocyte-macrophage Colony Stimulating Factor as Second-line Therapy for Advanced Non-small Cell Lung Cancer: Safety Run-in Results of a Multicenter, Single-arm, Phase II Trial

Jianjiao Ni, Yue Zhou, Lin Wu, Xinghao Ai, Xiaorong Dong, Qian Chu, Cheng‐Bo Han, Xiaofei Wang, Zhengfei ZhuResearch 2021 · DOI

Abstract

Objectives: The SWORD trial is the first multicenter, single-arm, phase II study assessing the safety and efficacy of a PD-1 inhibitor (Sintilimab), stereotactic body radiotherapy (SBRT), and granulocyte-macrophage colony stimulating factor (GM-CSF) in advanced non-small cell lung cancer (NSCLC) without sensitizing driver mutations. A safety run-in phase was conducted to determine the tolerability of the experimental treatment.

Materials and Methods: Twenty metastatic NSCLC patients who failed first-line chemotherapy were enrolled. They received SBRT (8Gy x 3) to one lesion, followed by Sintilimab (200 mg every 3 weeks) and GM-CSF (125 μg/m² d1-d14, cycle 1) within 2 weeks after SBRT.

Results: No patients had dose-limiting toxicities (DLTs). Eighteen patients experienced treatment-related adverse events (TRAEs), mostly grade 1 (fatigue, fever, ostealgia). Two grade 3 TRAEs occurred: liver enzyme elevation and transient acute heart failure. No grade 4 or 5 events were observed.

Conclusion: The combination of Sintilimab, SBRT, and GM-CSF is safe with manageable toxicities for advanced NSCLC.

Introduction

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality globally. While immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have significantly improved outcomes, only a minority of patients (15-20%) achieve a durable response. Many tumors are "cold," characterized by a lack of immune cell infiltration, which limits the efficacy of immunotherapy.

The SWORD trial explores a novel "triple threat" strategy to convert "cold" tumors into "hot" ones. This approach combines three synergistic modalities:

  1. SBRT (The Prime): High-dose radiation kills tumor cells, releasing tumor-associated antigens into the microenvironment.
  2. GM-CSF (The Boost): This cytokine promotes the maturation and recruitment of dendritic cells, which are essential for capturing and presenting the released antigens to T-cells.
  3. Sintilimab (The Unleash): A PD-1 inhibitor that prevents the tumor from "switching off" the immune response, allowing activated T-cells to attack the cancer systemically.

This report focuses on the safety run-in phase of the SWORD trial, evaluating the tolerability of this combination in the first 20 patients.

Methods and Patient Population

The SWORD trial (NCT04106180) is a multicenter, single-arm, Phase II study. The safety run-in phase enrolled 20 patients with metastatic NSCLC who had progressed after first-line chemotherapy and lacked sensitizing driver mutations (e.g., EGFR, ALK).

Treatment Regimen

The experimental protocol involved a specific sequence:

  • SBRT: 24 Gy delivered in three 8 Gy fractions to a single metastatic lesion. Target sites included the lung, lymph nodes, liver, and bone.
  • Sintilimab: 200 mg administered intravenously every 3 weeks, starting within 14 days of completing SBRT.
  • GM-CSF: 125 μg/m² administered daily for the first 14 days of the first treatment cycle.

Patient Characteristics

The study population consisted primarily of male patients (75%) with a median age of 61. Notably, all 20 patients had advanced disease with more than five metastatic lesions at baseline, and 75% had three or more metastatic organs involved.

Table 1: Baseline characteristics of the 20 patients enrolled in the safety run-in phase.

Results

The primary objective of the safety run-in was to identify Dose-Limiting Toxicities (DLTs) within a 30-day observation window.

Safety and Tolerability

No DLTs were observed among the 20 patients. While 90% (18/20) of patients experienced at least one treatment-related adverse event (TRAE), the majority were mild (Grade 1). The most frequent Grade 1 events included:

  • Fatigue (50%)
  • Fever (30%)
  • Ostealgia/Bone pain (20%)

Severe Adverse Events

Only two Grade 3 TRAEs were reported: one instance of elevated liver enzymes and one instance of transient acute heart failure. Both events were successfully managed with standard medical care. Importantly, no Grade 4 or Grade 5 (fatal) treatment-related events occurred during the study period.

Discussion

The safety run-in results of the SWORD trial demonstrate that the combination of Sintilimab, SBRT, and GM-CSF is well-tolerated in patients with advanced NSCLC. The absence of DLTs and the manageable nature of the observed TRAEs support the continued investigation of this triple-therapy regimen.

The occurrence of transient acute heart failure, while rare, highlights the importance of cardiac monitoring when combining immunotherapies with cytokines like GM-CSF. While the biological synergy of "prime-boost-unleash" is promising for overcoming immunotherapy resistance, larger cohorts are needed to fully characterize the safety profile and, more importantly, the clinical efficacy of this approach.

The SWORD trial continues to recruit participants toward its target of 56 patients. Future analyses will focus on the primary endpoint of Objective Response Rate (ORR) to determine if this combination can indeed trigger a systemic abscopal effect and improve survival outcomes for patients with advanced NSCLC.

Summary updated

Abstract

Abstract Objectives: The SWORD trial is the first multicenter, single arm, phase II study assessing the safety and efficacy of a PD-1 inhibitor (Sintilimab), stereotactic body radiotherapy (SBRT) and granulocyte-macrophage colony stimulating factor (GM-CSF) in advanced non-small cell lung cancer (NSCLC) without sensitizing driver mutations. A safety run-in phase was conducted to determine the tolerability of the experimental treatment. Materials and Methods: Twenty metastatic NSCLC patients who failed first-line chemotherapy were enrolled, and they received SBRT (8Gy x 3) to one lesion, followed by Sintilimab (200 mg d1, every 3 weeks, until disease progression, unacceptable toxicity, or up to 35 cycles) and GM-CSF (125 μg/m 2 d1-d14, cycle 1) within 2 weeks after SBRT. In addition, blood and tissue samples were serially collected for translational research. Results: Median age of the patients was 61 and all of them had more than 5 lesions at baseline. The sites of SBRT included lung (n=11), mediastinal lymph node (n=5), liver (n=1), abdominal lymph node (n=1), pleural nodule (n=1) and vertebra (n=1). No patients had dose-limiting toxicities (DLTs) and 18 patients experienced treatment-related adverse event (TRAE). The most common TRAEs were fatigue (50%), fever (30%), and ostealgia (20%), and they all were grade 1. Only 2 grade 3 TRAEs were observed, including elevation of liver enzymes in one and transient acute heart failure in another. No grade 4 or 5 AE was observed. Conclusion: Sintilimab, SBRT and GM-CSF for advanced NSCLC is safe with manageable TRAEs and the trial continues to recruit participants. Trial registration: ClinicalTrials.gov, NCT04106180. Registered 26 September 2019, SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC - Tabular View - ClinicalTrials.gov
BibTeX
@inproceedings{ni2021sintilimab,
  author = {Jianjiao Ni and Yue Zhou and Lin Wu and Xinghao Ai and Xiaorong Dong and Qian Chu and Cheng‐Bo Han and Xiaofei Wang and Zhengfei Zhu},
  title = {{Sintilimab, Stereotactic Body Radiotherapy and Granulocyte-macrophage Colony Stimulating Factor as Second-line Therapy for Advanced Non-small Cell Lung Cancer: Safety Run-in Results of a Multicenter, Single-arm, Phase II Trial}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-578138/v1},
}
Figure